Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12091397 Dihydroquinolinones for medical treatment

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

C4 Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Annick Goergler0

Eric Andre Kusznir0

Fabian Dey0

Moreno Attilio Wichert0

Roger Norcross0

Adrian Britschgi0

Date of Patent

September 17, 2024

0

Patent Application Number

178787530

Date Filed

August 1, 2022

0

Patent Citations

US Patent 9249161 Bromodomain inhibitors and uses thereof

0

US Patent 10646575 Heterocyclic degronimers for target protein degradation

0

US Patent 10660968 Spirocyclic degronimers for target protein degradation

0

US Patent 10849982 C3-carbon linked glutarimide degronimers for target protein degradation

0

US Patent 10905768 Heterocyclic degronimers for target protein degradation

0

US Patent 11185592 Spirocyclic degronimers for target protein degradation

0

US Patent 11254672 Dihydrobenzimidazolones for medical treatment

0

US Patent 11401256 Dihydroquinolinones for medical treatment

0

...

Patent Primary Examiner

Medhanit W Bahta

0

Patent abstract

The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12091397 Dihydroquinolinones for medical treatment

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool